IgG4-related ophthalmic disease masquerading as ciliary body tumors and scleritis in both eyes: a case report.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
09 Mar 2023
Historique:
received: 17 05 2022
accepted: 16 02 2023
entrez: 9 3 2023
pubmed: 10 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

To report a rare case of IgG4-related ophthalmic disease (IgG4-ROD) manifesting as intraocular masses and scleritis in both eyes in a 61-year-old male and to investigate the changes in multimodal imaging features of the lesion sites and helper T-cell type 1 (Th 1)/Th 2/Th 17 cytokine levels in the aqueous humor. A patient with IgG4-ROD seemingly manifested with an intraocular tumor in the left eye and sequentially, with an inflammatory mass in the ciliary body and scleritis in the right eye. The patient complained of vision loss of 6 months duration in the left eye at his first visit. With a preliminary diagnosis of an intraocular tumor, enucleation of the left eyeball and histopathological examination were performed. Approximately 3 months later, the patient started to experience headache, eye pain, and declining vision in the right eye. Ophthalmic imaging revealed a ciliary mass and scleritis. Th 1/Th 2/Th 17 cytokine levels and multimodal imaging findings were analyzed before and after corticosteroid treatment. Histopathological examination and immunohistochemistry (IHC) of the enucleated left eye demonstrated lymphoplasmacytic infiltration with an IgG4+/IgG+ cell ratio of approximately 40%, pointing to the diagnosis of probable IgG4-ROD. Long-term treatment with corticosteroids led to significant improvement in the signs and symptoms of the left eye. Th 1/Th 2/Th 17 cytokine profile monitoring of the aqueous humor and multimodal imaging of the right eye showed gradual regression of the mass and attenuation of ocular inflammation during treatment. Patients with an atypical presentation of IgG4-ROD, such as intraocular masses and scleritis, are likely to experience a significant delay in diagnosis. This case demonstrates the significance of IgG4-ROD in the differential diagnosis of intraocular tumors and ocular inflammation. IgG4-RD is a newly diagnosed disease with multi-organ involvement and little is known about its pathogenesis, particularly in the eye. The present case will open new challenges in the clinico-pathological diagnosis and research of this disease. Combined investigations of multimodal imaging and cytokine level detection of intraocular fluid provide a new and effective way to monitor disease progression.

Sections du résumé

BACKGROUND BACKGROUND
To report a rare case of IgG4-related ophthalmic disease (IgG4-ROD) manifesting as intraocular masses and scleritis in both eyes in a 61-year-old male and to investigate the changes in multimodal imaging features of the lesion sites and helper T-cell type 1 (Th 1)/Th 2/Th 17 cytokine levels in the aqueous humor.
CASE PRESENTATION METHODS
A patient with IgG4-ROD seemingly manifested with an intraocular tumor in the left eye and sequentially, with an inflammatory mass in the ciliary body and scleritis in the right eye. The patient complained of vision loss of 6 months duration in the left eye at his first visit. With a preliminary diagnosis of an intraocular tumor, enucleation of the left eyeball and histopathological examination were performed. Approximately 3 months later, the patient started to experience headache, eye pain, and declining vision in the right eye. Ophthalmic imaging revealed a ciliary mass and scleritis. Th 1/Th 2/Th 17 cytokine levels and multimodal imaging findings were analyzed before and after corticosteroid treatment. Histopathological examination and immunohistochemistry (IHC) of the enucleated left eye demonstrated lymphoplasmacytic infiltration with an IgG4+/IgG+ cell ratio of approximately 40%, pointing to the diagnosis of probable IgG4-ROD. Long-term treatment with corticosteroids led to significant improvement in the signs and symptoms of the left eye. Th 1/Th 2/Th 17 cytokine profile monitoring of the aqueous humor and multimodal imaging of the right eye showed gradual regression of the mass and attenuation of ocular inflammation during treatment.
CONCLUSIONS CONCLUSIONS
Patients with an atypical presentation of IgG4-ROD, such as intraocular masses and scleritis, are likely to experience a significant delay in diagnosis. This case demonstrates the significance of IgG4-ROD in the differential diagnosis of intraocular tumors and ocular inflammation. IgG4-RD is a newly diagnosed disease with multi-organ involvement and little is known about its pathogenesis, particularly in the eye. The present case will open new challenges in the clinico-pathological diagnosis and research of this disease. Combined investigations of multimodal imaging and cytokine level detection of intraocular fluid provide a new and effective way to monitor disease progression.

Identifiants

pubmed: 36894878
doi: 10.1186/s12886-023-02822-7
pii: 10.1186/s12886-023-02822-7
pmc: PMC9999535
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Immunoglobulin G 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

92

Informations de copyright

© 2023. The Author(s).

Références

Rheumatology (Oxford). 2013 Apr;52(4):679-83
pubmed: 23258649
Taiwan J Ophthalmol. 2018 Jan-Mar;8(1):9-14
pubmed: 29675343
Case Rep Ophthalmol. 2019 Aug 30;10(2):299-303
pubmed: 31579117
Insights Imaging. 2021 Jun 3;12(1):66
pubmed: 34080069
Ultrasound Med Biol. 1997;23(3):365-75
pubmed: 9160904
Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):531-8
pubmed: 24384801
Br J Ophthalmol. 2016 Oct;100(10):1409-11
pubmed: 26719494
Mod Rheumatol. 2012 Feb;22(1):21-30
pubmed: 22218969
Indian J Ophthalmol. 2016 Aug;64(8):601-3
pubmed: 27688285
Mod Rheumatol. 2014 May;24(3):471-6
pubmed: 24252013
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
PLoS One. 2013;8(2):e52385
pubmed: 23405064
Sci Rep. 2015 Aug 27;5:13539
pubmed: 26311608
Mod Rheumatol. 2014 Jan;24(1):195-8
pubmed: 24261778
Jpn J Ophthalmol. 2015 May;59(3):201
pubmed: 25707353
Pathol Int. 2008 Aug;58(8):465-70
pubmed: 18705764
Curr Opin Ophthalmol. 2017 Nov;28(6):617-622
pubmed: 28858963
Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):491-7
pubmed: 24318531
Medicine (Baltimore). 2017 Mar;96(10):e6205
pubmed: 28272212

Auteurs

Jiayue Ma (J)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China.

Manyun Xie (M)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China.

Kejun Long (K)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China.

Mi Deng (M)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China.

Liang Zhou (L)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China. zhouliang12@csu.edu.cn.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China. zhouliang12@csu.edu.cn.

Jing Luo (J)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410011, China. luojing001@csu.edu.cn.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China. luojing001@csu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH